NYSDA Publications

NIH Issues Research Findings on Immune Modulator Drugs Improving Survival Rates for Hospitalized COVID-19 Patients

The National Institutes of Health (NIH) has issued research findings showing that immune modulator drugs improved survival for people hospitalized with novel coronavirus (COVID-19).  NIH notes that treating adults hospitalized with COVID-19 with infliximab or abatacept – drugs widely used to treat certain autoimmune diseases – did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.  To read the NIH announcement and summary of its research findings on immune modulator drugs improving survival rates for hospitalized COVID-19 patients, use the link below.